Lexington County-based Nephron Pharmaceuticals is being sued by another drug manufacturer, which claims Nephron products are being marketed as a replacement for its own drug without FDA approval.
After nephron-sparing treatment for RCC, patients with local recurrence had a higher mortality risk than patients without recurrence.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback